The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

Shen, T; Hu, XQ; Liu, X; Subbiah, V; Mooers, BHM; Wu, J

Wu, J (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73106 USA.; Wu, J (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73106 USA.

NPJ PRECISION ONCOLOGY, 2021; 5 (1):

Abstract

Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索